|
|
|
|
The relationship between cancer and blood vessels ?span style="font:7.0pt "Times New Roman""> The blood vessel is the means of nutrition and metabolism of the cancer. ?span style="font:7.0pt "Times New Roman""> The blood vessel is the fast, convenient and direct way to transform the cancer. ?span style="font:7.0pt "Times New Roman""> The growth and transformation of the original cancer are both dependent on angiogenesis. Anti-angiogenic therapy ?span style="font:7.0pt "Times New Roman""> Recurrence and metastasis are the basic reasons for the failure of cancer treatment. ?span style="font:7.0pt "Times New Roman""> The blood vessel system of tumors has already become a promising target for anticancer treatment. ?span style="font:7.0pt "Times New Roman""> Anti-angiogenic therapy is one way to cut off the supply of nutrition to the cancer. The other is to block or obstruct the transfer to other areas. It has become a very important element in the synthetic treatment of cancer. The character of inhibited angiogenesis of cancer ?span style="font:7.0pt "Times New Roman""> Once cancer has occurred more blood vessel formation is already taking place, so it is a very distinctive characteristic. ?span style="font:7.0pt "Times New Roman""> The first arrival point when the medicine is injected into the vein is the epithelial cell of the blood vessel embedded in the tumor. The epithelial cells are exposed to the flowing blood stream so the medicine can have a direct effect. This results in small doses being required giving high efficiency with minimal side-effects. ?span style="font:7.0pt "Times New Roman""> The gene expression is comparatively stable in the epithelial cells, so it is not easy to produce resistance to the medicine. ?span style="font:7.0pt "Times New Roman""> Magnification effects. With only a limited amount of damage to the epithelial cells of the blood vessel, a large degree of inhibition can be achieved in the growing cancer cells through breaking or attacking the epithelial cells. ?span style="font:7.0pt "Times New Roman""> The majority of cancers are all observed to have an active process of blood vessel formation, so this is why anti-angiogenesis has such a broad spectrum of activity.
Pharmacokinetic parameters
The time dependant concentration of Rg3 in the blood after a healthy recipient took 3.2mg/Kg of Rg3 Description of graphical results (Above) ?span style="font:7.0pt "Times New Roman""> Rg3 shows good results of absorption when taken orally, conforming to a two parameter matrix. 15-30 minutes after taking the medicine some of the material can be observed in the blood. After 1-1.5 hours the peak concentration in the blood is observed. The half-life observed is 4.84 ?1.41 hours.
The chromatograph of the urine of the mice shows the Rg3 medicine ingested is eliminated through the urine.
The distribution of medicine in the cancer and tissue
Concentration distribution in S-180 rat cancer after taking RG3 at 18mg/Kg as measured by High performance liquid chromatography. The peak concentration of RG3 is observed in the cancer itself but is also widely distributed in the other organs and tissues showing theoretical basis for clinical use. Toxicological Experiments
Multiple centres of clinical research of RG3 single treatment on non-small cell cellular lung cancer
There were 59 none small cancer patients in a group. After RG3 treatment there were 5 cases of effective treatment, a rate of 8.47%.
The amount of general improvement following treatment with RG3. The majority 86.4% (51 cases from 59 in total) showed significant or definite results. Statistical deviation is <0.001 demonstrating the statistical significance is proved.
The research showed that RG3 has a significant improvement on the quality of life for the patients. After treatment 39 cases showed improvement, 19 cases were stable and only 1 case showed a reduction. Statistical deviation is <0.001 demonstrating the statistical significance is proved. Results of clinical stage IV investigations According to SFDA regulations and based on the principles of clinical research of a traditional Chinese medicine. There were 49 hospitals taking part in the stage IV clinical trials. From March 2000 to June 2002 many types of cancer were investigated ranging from gastric cancer, breast cancer, lymphoma, ovarian cancer, pulmonary cancer, hepatic cancer. The results of the scientific investigation show the effectiveness of the Rg3 treatment. When using RG3 to cure pulmonary cancer the remission rate is 10 cases from 132 this being an effective 7.58% rate. 95.4% of cases remained stable.
Total number of cases of pulmonary cancer is 645. 240 cases showed efficient treatment which is an efficiency rate of 37.21%
Total number of cases of hepatic cancer is 108. 38 cases showed efficient treatment which is an efficiency rate of 35.18%
Results showed at the clinical trial stage IV there was a significant improvement in the clinical symptoms following co-operative treatment with chemotherapy of pulmonary cancer, gastric cancer, breast cancer, hepatic cancer, ovarian cancer and lymphoma. The rate of efficiency is 61.36%.
The life quality of the patients with substantive cancer improves significantly when RG3 is used in conjunction with chemotherapy. Up to 23.99% is observed when a Kanofsky calculation is made.
Stage IV clinical trials were performed to evaluate the side effects of RG3. No abnormal function was observed in the heart, liver or kidney. The main side effects were dryness of the mouth and throat and some mouth ulcer formation. All conditions revert automatically and gradually. The invention of anti-angiogeneic therapy is a new way of treatment to inhibit the growth and transformation. Choosing a reasonable treatment schedule, proper time and united with conventional treatment, operation, chemotherapy, radiotherapy etc. Anti-angiogeneic therapy has already become one of the main factors in efficiently inhibiting recurrence and transformation of cancer. The discovery brings hope that cancer will be a curable disease in future.
1. Inhibition of recurring and metastasis of cancer following operation, chemotherapy and radiotherapy. 2. Combined treatment can significantly improve the effects of chemotherapy and radiotherapy. Reduce the toxicity of side effects. Improve the immune system of the body. 3. Significantly improves appetite, improves the emotional state of the patient, reduces pain, enables weight gain and generally improves life quality.
|
|
Send mail to
webmaster@yatai.com with
questions or comments about this web site.
|
